ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION by A. V. Rudakova

“…</strong> The analysis was performed with the perspective of the health care budget with 5 year horizon period and by the pharmacoeconomic model developed by Pharmerit International (Rotterdam, Netherlands) and adapted for the RF. …”
Get full text

Outcomes and risk factors for delayed-onset postoperative respiratory failure: a multi-center case-control study by the University of California Critical Care Research Collaborativ... by Jacqueline C. Stocking, Christiana Drake, J. Matthew Aldrich, Michael K. Ong, Alpesh Amin, Rebecca A. Marmor, Laura Godat, Maxime Cannesson, Michael A. Gropper, Patrick S. Romano, Christian Sandrock, Christian Bime, Ivo Abraham, Garth H. Utter

Get full text

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION by L. A. Balykova, N. M. Selezneva, E. I. Gorshenina, O. I. Shepeleva, N. V. Kirichenko, E. N. Simakina, K. B. Kolontarev, D. Yu. Pushkar, D. N. Zemskov, K. Ya. Zaslavskaya, S. M. Noskov, A. V. Taganov, P. A. Bely

“…The data obtained demonstrate a clinical and pharmacoeconomic feasibility of including the fixed (nirmatrelvir + ritonavir) combination in the COVID-19 treatment regimen.…”
Get full text

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study) by Van Aken E, Favreau M, Ramboer E, Denhaerynck K, MacDonald K, Abraham I, Brié H

“…Elisabeth Van Aken,1,2 M&eacute;r&eacute;dis Favreau,3 Eva Ramboer,3 Kris Denhaerynck,4,5 Karen MacDonald,4 Ivo Abraham,4,6&ndash; 8 Heidi Bri&eacute;3 1Department of Ophthalmology, AZ Sint-Elisabeth, Zottegem, Belgium; 2Department of Head and Skin, Ghent University, Ghent, Belgium; 3Medical Department, Novartis Pharma, Vilvoorde, Belgium; 4Department of Research and Consulting, Matrix45, Tucson, AZ, USA; 5Department of Public Health, University of Basel, Basel, Switzerland; 6Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson, AZ, USA; 7Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; 8Department of Family and Community Medicine, College of Medicine &ndash; Tucson, University of Arizona, Tucson, AZ, USACorrespondence: Heidi Bri&eacute;N.V. …”
Get full text

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk? by Victor M. Rivera

“…The main priority should always be the protection and well-being of the patient irrespectively of therapy availability or pharmacoeconomic issues.…”
Get full text

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degene... by Rakic JM, Leys A, Bri&amp;eacute; H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, MacDonald K, Abraham I

“…Jean-Marie Rakic,1 Anita Leys,2 Heidi Bri&eacute;,3 Kris Denhaerynck,4 Christy Pacheco,4 Stefaan Vancayzeele,3 Christine Hermans,3 Karen MacDonald,4 Ivo Abraham4,5 1Department of Ophthalmology, Centre Hospitalier Universitaire de Li&egrave;ge, Site du Sart Tilman, Li&egrave;ge, Belgium; 2Leuven University Eye Hospital, Leuven, Belgium; 3Novartis Pharma, Vilvoorde, Belgium; 4Matrix45, Tucson, AZ, USA; 5Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson, AZ, USA Introduction: The aim of this study was to examine ranibizumab treatment patterns in "real-world" practice and clinical settings, as well as to assess quality of life outcomes over a 24-month period. …”
Get full text

Qualidade de vida em pacientes hipertensos e validade concorrente do Minichal-Brasil Quality of life in hypertensive patients and concurrent validity of Minichal-Brazil by Ana Carolina Melchiors, Cassyano Januário Correr, Roberto Pontarolo, Felipe de Oliveira de Souza Santos, Rodrigo Augusto de Paula e Souza

“…<br>BACKGROUND: Health-Related Quality of Life Questionnaires (HRQOL) are humanistic outcome measure instruments both in clinical and in pharmacoeconomic studies. However, they should have their psychometric parameters evaluated so as to reflect the individual subjective assessment of quality of life. …”
Get full text

Interprofessional Collaboration between ICU Physicians, Staff Nurses, and Hospital Pharmacists Optimizes Antimicrobial Treatment and Improves Quality of Care and Economic Outcome by Stephan Schmid, Sophie Schlosser, Karsten Gülow, Vlad Pavel, Martina Müller, Alexander Kratzer

“…The suggestions of the hospital pharmacist for optimization can be divided into the following categories (i) indication for and selection of therapy (43.6%), (ii) optimization of dosing (27.6%), (iii) drug interactions (9.4%), (iv) side effects (4.1%), and (v) other pharmacokinetic, pharmacodynamic, and pharmacoeconomic topics (15.3%). These suggestions were discussed among the interprofessional team at the MICU; 86.1% were consequently implemented and the prescription of antibiotics was changed. …”
Get full text

Análisis coste-efectividad del empleo de celecoxib en el tratamiento de la artrosis Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis by A. Moreno, E. Vargas, J. Soto, J. Rejas

“…Material and Methods: This cost-effectiveness analysis was designed through a pharmacoeconomic model; each effectiveness unit was defined as each year of life gained after the ingestion of celecoxib or NSAIDs. …”
Get full text

Comparative assessment of efficacy and toxicity of R-DA-EPOCH and R-mNHL-BFM-90 induction courses in the treatment of patients with diffuse large B-cell lymphoma with poor prognost... by M. O. Bagova, A. U. Magomedova, S. K. Kravchenko, Ya. K. Mangasarova, O. V. Margolin, E. S. Nesterova, L. G. Gorenkova, A. E. Misyurina, E. A. Fastova, F. E. Babaeva, K. A. Sychevskaya, S. M. Kulikov, Yu. A. Chabaeva, V. G. Savchenko

“…As part of this study, the analysis of pharmacoeconomic factors and effectiveness of combined immunochemotherapy R-DA-EPOCH and R-mNHL-BFM-90 in patients with prognostically unfavorable DLBCL had been performed. …”
Get full text

ESTUDO DE AVALIAÇÃO DO CONSUMO DE RECURSOS HOSPITALARES ASSOCIADOS À ADMINISTRAÇÃO DE TRASTUZUMAB by Sofia Andrade Andrade, Ana Santos, Aldiro Magano Magano, Alexandra Madureira, Ana Vinagre, Carlos Góis, Fátima Falcão, Graça André, Inês Lima, Maria José Alves, Maria Nazaré Rosado, Patrícia Cavaco, Paula Rolim, Rita Lopes

Get full text

Comparison of the CQ-11D, SF-6Dv1 and EQ-5D-3L Contemporaneous Utility Scores in Patients with Chronic Disease by WANG Wei, XIE Shitong, ZHOU Jiameng, PAN Jie, ZHU Wentao

Get full text

Recommendations for patient involvement in health technology assessment in Central and Eastern European countries by Ivett Jakab, Ivett Jakab, Maria Dimitrova, François Houÿez, Tamás Bereczky, Miroslava Fövényes, Zorana Maravic, Ivica Belina, Christian Andriciuc, Krisztina Tóth, Krisztina Tóth, Oresta Piniazhko, Rok Hren, Rok Hren, Iñaki Gutierrez-Ibarluzea, Marcin Czech, Tomas Tesar, Maciej Niewada, László Lorenzovici, László Lorenzovici, Maria Kamusheva, Manoela Manova, Manoela Manova, Alexandra Savova, Alexandra Savova, Zornitsa Mitkova, Konstantin Tachkov, Bertalan Németh, Zsuzsanna Ida Petykó, Zsuzsanna Ida Petykó, Dalia Dawoud, Diana Delnoij, Saskia Knies, Wim Goettsch, Wim Goettsch, Zoltán Kaló, Zoltán Kaló

Get full text